Africa institutional business volatility
Africa anti-malarial business declined ~42% in 9M FY25 due to lower Global Fund procurement; future depends on donor funding, which is uncertain given U.S. policy changes.
AJANTPHARM / Q3-FY25 / risks
Keep the risk register visible.
Ajanta Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
U.S. generic price erosion and launch delays
U.S. generics growth is dependent on new product launches and limited competition; any delays or higher-than-expected price erosion could impact growth.
Margin pressure from new therapy investments
Entry into gynecology and nephrology in India and CNS in Asia will increase SG&A and personnel costs, potentially pressuring near-term margins.
Tax rate increase in FY27
Management indicated tax rate may rise from 24% to ~25% in FY27 as some exemptions expire, impacting net profitability.